Iovance Biotherapeutics, Inc. (0JDK.L)
| Previous close | 11.48 |
| Open | 11.50 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 11.44 - 11.72 |
| 52-week range | 3.22 - 18.31 |
| Volume | |
| Avg. volume | 53,275 |
| Market cap | 15.768M |
| Beta (5Y monthly) | 0.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.30 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (“Iovance” or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on April 18, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 79,310 shares of Iovance’s common stock to thirty-seven new,
Simply Wall St.Market Sentiment Around Loss-Making Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA ) is possibly approaching a major achievement in its business, so we would...
ZacksIovance (IOVA) Stock Surges More Than 60% YTD: Here's Why
Iovance (IOVA) surges on the recent FDA approval for its lead pipeline drug as the first individualized, one-time cell therapy for certain patients with melanoma.
